Gilead Sciences | GILD - 应收帐款人





应收帐款人 更改 日
AbbVie USD 12.48B 110M 2026-03
Agios Pharmaceuticals USD 16.13M 5.56M 2026-03
ALKERMES USD 456.48M 48.85M 2026-06
Alnylam Pharmaceuticals USD 912.74M 28.78M 2026-06
Amgen USD 10.23B 1.09B 2026-06
Biogen USD 1.79B 76.6M 2026-03
BioMarin Pharmaceutical USD 1.06B 157.13M 2026-06
Bristol-Myers Squibb USD 13.83B 535M 2026-06
Coherus Biosciences USD 18.42M 232.08M 2025-12
Eli Lilly USD 23.48B 2.3B 2026-06
Gilead Sciences USD 5.06B 314M 2026-06
GlaxoSmithKline GBP 8.07B 137M 2026-06
Glaxosmithkline GBP 10.49B 40.6M 2026-03
Incyte USD 1.13B 73.7M 2026-06
J&J USD 22.54B 1.21B 2026-03
Merck USD 12.21B 435M 2026-03
Moderna USD 17M 54M 2026-06
Neurocrine Biosciences USD 887M 118.9M 2026-06
Novartis USD 9.85B 252M 2026-06
Pfizer USD 16.19B 19M 2026-06
PTC Therapeutics USD 219.92M 38.3M 2026-03
Puma Biotechnology USD 28.1M 3.52M 2024-06
Regeneron Pharmaceuticals USD 6.57B 834.4M 2026-06
Sangamo BioSciences USD 581K 110K 2024-06
Sanofi EUR 492M 10M 2026-06
Sarepta Therapeutics USD 393.8M 154.11M 2026-06
United Therapeutics USD 310.3M 1.7M 2026-06
Vertex Pharmaceuticals USD 2.13B 138.2M 2026-06